BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Suneva Medical Selects Quinnova Pharmaceuticals, Inc. to Co-Promote ReFissa® -Topical RX Facial Skin Care Treatment URL New Relationship Will Expand the Dermatology Prescriber Base for ReFissa, Tretinoin Cream, USP (Emollient) 0.05%


6/21/2013 9:31:36 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO & JAMISON, Pa. (June 4, 2013) – Suneva Medical, Inc., a privately-held aesthetics company, today announced that it has selected Quinnova Pharmaceuticals, LLC, a premier provider of therapeutic skin and wound products in the United States, to co-promote ReFissa.

ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin. The Suneva/Quinnova relationship will expand the awareness and prescriber base of ReFissa in the U.S. dermatology community.

“Quinnova has structured its unique delivery platforms to provide superior products that address a variety of skin conditions,” said Jeffrey Day, Quinnova’s President, CEO and Founder.

“As one of the most effective treatments for fine facial wrinkles, ReFissa strengthens our product portfolio, adding a coveted topical aesthetic solution to our portfolio and enhancing our value among healthcare professionals.”

Nicholas Teti, Chairman and CEO of Suneva Medical added: “With Quinnova, we are able to access a strong and growing pharmaceutical dermatology sales team that is highly capable of driving ReFissa’s retail pharmacy prescription growth.”

To learn more about ReFissa, visit www.refissa.com. For information on Quinnova Pharmaceutical products, visit www.quinnova.com.

Media interested in speaking with a Suneva Medical representative should contact Melody Demel at 619-234-0345 or suneva@formulapr.com.

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES